DC
Dishman Carbogen Amcis Ltd (DCAL)
₹115.57
Mkt cap
₹1,899 Cr
P/E ratio
—
P/B
0.27
Div yield
0.00%
ROE
1.58%
ROCE
3.14%
EPS (TTM)
—
Book value
₹426
52W range
115–274
Sector
Healthcare
Price history
Previous close
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries. [1]
NSE DCALBSE 540701
Health check
Cautious
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−57.87% from high₹116
₹115+0.50% from low₹274
Current
₹115.57
Prev close
₹118.53
Day
−2.50%
Price performance
1D
−2.22%
1W
−32.97%
1M
−17.23%
3M
−32.78%
6M
−45.30%
1Y
−53.49%
YTD
−54.64%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 | 507 | |
| YoY Sales growth | -4% | +2% | +6% | -28% | +35% | +5% | +9% | +35% | -17% | +5% | +19% | -4% | -22% | |
| Expenses | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 | 461 | |
| Operating Profit | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 | 46 | |
| OPM % | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% | 9% | |
| Other Income | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 | 4 | |
| Interest | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 | 40 | |
| Depreciation | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 | 90 | |
| Profit before tax | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 | -81 | |
| Tax % | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% | 53% | 13% | -18% | |
| Net Profit | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 | -67 | |
| EPS in Rs | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 | -4.26 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202659.32%Promoter
Promoters59.32%
FIIs6.96%0.10
DIIs1.65%0.41
Public32.05%0.29
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,871.50 | 36.49 | 4,49,036 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,049.00 | 85.83 | 2,93,316 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,610.70 | 80.78 | 1,75,376 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,322.50 | 93.66 | 1,25,488 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,202.00 | 26.46 | 1,19,900 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,398.20 | 41.71 | 1,16,788 | 0.57% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,417.00 | 36.86 | 1,14,478 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Dishman Carbogen | ₹121.15 | — | 1,899 | 0.00% | −67 | −202.24% | 507 | −22.26% | 3.14% |
| Median: 160 Co. | ₹439.32 | 32.75 | 2,001 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports10
Concall transcripts77
PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025PPTSep 2025RECSep 2025TranscriptSep 2025PPTSep 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 16 Nov - Audio recording of 16 Nov 2026 earnings call for Q2 FY2026-27 results available on website.Announcement under Regulation 30 (LODR)-Investor Presentation 16 Nov - Pls. find enclosed herewith Investor Presentation.Board Meeting Outcome for Unaudited Financial Results And Statutory Auditors Limited Review Report For The Second Quarter And Half Year Ended On 30/09/2026. 13 Nov - Dishman Carbogen Amcis approved Q2 and H1 FY2026 unaudited results on 13 November 2026.Unaudited Financial Results And Statutory Auditors Limited Review Report For The Second Quarter And Half Year Ended On 30/09/2026. 13 Nov - Dishman Carbogen Amcis approved Q2 FY2026-27 results; consolidated net loss Rs124.61 crore, standalone loss Rs49.18 crore.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Nov - Pls. find enclosed herewith intimation of Conference Call to be held on 16th November 2026.






